How long till semaglutide leaves your body — and why it matters

What the pharmacokinetic data actually show

The seven-day half-life is not an estimate, it is drawn from the pharmacokinetic studies that supported semaglutide's European and UK regulatory submissions, summarised in the medicine's Summary of Product Characteristics on the eMC. A half-life of seven days means that after one missed weekly dose, roughly half the previous week's drug remains active. After two weeks without injecting, about a quarter lingers. Working through the maths: five half-lives, or approximately 35 days, reduces circulating semaglutide to around 3% of peak steady-state levels. That is generally considered the threshold at which pharmacological effects become negligible for most people.

In practice, gastric emptying returns to its pre-treatment rate over a similar timeframe, which is why appetite (and, for many people, food noise) tends to creep back gradually rather than switching off overnight. The NHS medicines page for semaglutide confirms the weekly dosing schedule and flags that effects persist beyond each injection, which is precisely because of this long half-life.

If you want a fuller breakdown of the clearance curve, our page on how long semaglutide stays in the body walks through the pharmacokinetics in plain language. One practical check you can do right now: look up the date of your last or most recent dose and count forward 35 days, and our guide to how long semaglutide lasts in the body explains exactly what is happening at each stage of that countdown. That date is roughly when semaglutide will have cleared to trace levels. It takes under a minute and gives you a concrete reference point for any conversation with your prescriber or GP.

Why the clearance timeline matters for contraception and surgery

Two situations where semaglutide's lingering presence has real clinical consequences are oral contraception and planned surgery. Because semaglutide slows gastric emptying, it can reduce how much of an oral contraceptive pill is absorbed during the hours after you swallow it. NHS England's guidance on weight-management injections notes that patients on semaglutide should discuss contraception options with their healthcare team.

For surgery, the concern is different. Slowed gastric emptying raises the risk of regurgitation under general anaesthesia, a serious complication. This risk does not disappear the moment you stop injecting; given the five-week clearance window, anaesthetists need to know when you last took semaglutide, not just whether you are currently prescribed it. The standard advice is to tell every member of your surgical and anaesthetic team that you are on, or have recently been on, a GLP-1 medicine.

For fertility planning, the MHRA advises using effective contraception while taking semaglutide and for a defined wash-out period before trying to conceive. The exact recommended interval is set out in the Patient Information Leaflet; your prescriber can confirm the current guidance for your situation. This is not a decision to make by counting on your fingers alone.

What happens to weight and appetite after semaglutide clears

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4mg for 68 weeks and recorded an average weight reduction of around 15%. The extension data, and a separate withdrawal study, showed that a substantial proportion of weight lost during treatment returned within a year of stopping, without a structured lifestyle programme running alongside. This is not a failure of willpower. Semaglutide suppresses appetite by acting on GLP-1 receptors in the brain and gut; once the drug clears, those signals revert.

That rebound pattern is part of why clinicians think carefully about when and how to stop treatment, rather than simply switching it off. If you are considering stopping, our page on stopping Wegovy safely covers what the evidence says about tapering versus abrupt cessation. Results and clearance are two sides of the same coin, the drug works while it is present, and clears on a predictable schedule when it is not.

How quickly weight loss begins follows a similar pharmacokinetic logic. If you are earlier in treatment and wondering when the medicine starts to do something noticeable, our page on how long till semaglutide works explains the early-weeks picture.

Stopping, pausing or switching: the clearance window in context

People stop semaglutide for a range of reasons, planned pregnancy, surgery, a supply interruption, or a clinical decision to try a different medicine. Whatever the reason, the five-week clearance window means the drug does not simply vanish after the last pen. Side effects that have been present, including nausea or fatigue, will resolve within that window for most people. But so will the appetite-suppressing effect, which can catch people off guard if they expect an immediate return to normal hunger patterns.

Switching to tirzepatide, the dual GIP and GLP-1 receptor agonist available in the UK as Mounjaro, involves its own titration schedule and a prescriber assessment. The clearance windows of both medicines are relevant to safe switching timing. Our Wegovy overview sets out what the medicine is licensed for and how treatment works from the first dose through to maintenance.

If you are weighing up treatment options or thinking about cost as part of your decision, the Wegovy cost guide explains what private prescriptions typically include and what to watch for when comparing prices. And if you are at the point of deciding whether to start or restart, checking your eligibility with our prescribers is the right next step.